CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-17 | Sachs Jessica Chief Medical Officer | Shares withheld for taxes | −154,716 | $39.45 | $6.1M | 216,580 |
| 2025-12-17 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2025-12-17 | Kearns Evan Chief Legal Officer | Grant or award | +40,000 | 40,000 | ||
| 2025-12-17 | Kearns Evan Chief Legal Officer | Grant or award | +260,000 | 300,000 | ||
| 2025-12-17 | Kearns Evan Chief Legal Officer | Shares withheld for taxes | −125,602 | $39.45 | $5.0M | 174,398 |
| 2025-12-17 | Kearns Evan Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2025-12-17 | Green John L. Chief Financial Officer | Grant or award | +50,000 | 53,841 | ||
| 2025-12-17 | Green John L. Chief Financial Officer | Grant or award | +300,000 | 353,841 | ||
| 2025-12-17 | Green John L. Chief Financial Officer | Shares withheld for taxes | −145,007 | $39.45 | $5.7M | 208,834 |
| 2025-12-17 | Green John L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2025-10-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +1,642 | 1,642 | ||
| 2025-07-10 | Fairmount Funds Management LLC Director | Purchase | +2,777,777 | $9.00 | $25.0M | 9,003,418 |
| 2025-07-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +3,314 | 3,314 | ||
| 2025-06-04 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2025-06-04 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2025-06-04 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2025-06-04 | Shegog Todd Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2025-06-04 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2025-06-04 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2025-04-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +3,788 | 3,788 |
Page 3 of 7 · 131 trades